Literature DB >> 30671977

Review article: unanswered clinical and research questions in autoimmune hepatitis-conclusions of the International Autoimmune Hepatitis Group Research Workshop.

Jessica K Dyson1, Eleonora De Martin2, George N Dalekos3, Joost P H Drenth4, Johannes Herkel5, Stefan G Hubscher6, Deirdre Kelly6, Marco Lenzi7, Piotr Milkiewicz8,9, Ye H Oo6, Michael A Heneghan10, Ansgar W Lohse5.   

Abstract

BACKGROUND: Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease that results in substantial morbidity and mortality with many unanswered clinical and research questions. Improved understanding of disease pathogenesis, including the extra-hepatic manifestations of AIH, may allow targeted treatments with greater efficacy and fewer associated adverse events. AIM: To identify the spectrum of unanswered clinical and research questions facing care providers in the management of patients with autoimmune hepatitis (AIH).
METHODS: The International Autoimmune Hepatitis Group initiated a series of research workshops to start to address these questions. Key issues were discussed in small group sessions with collation of all discussions to be summarised in this manuscript.
RESULTS: Key issues were identified as: the need for better understanding of disease pathogenesis, standardisation of the methods and assays used to evaluate autoantibodies in AIH, refinement of the histopathological criteria for "typical" or "compatible" AIH, focus on the interaction with non-alcohol related fatty liver disease, how to treat acute severe AIH, better assessment of quality of life in adults and paediatrics, standardising use of standard, third-line and experimental therapies in AIH and search for biomarkers early in the disease course that predict outcome.
CONCLUSION: This workshop has outlined the key unanswered clinical and research questions to help to define the research agenda in AIH.
© 2019 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30671977     DOI: 10.1111/apt.15111

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  10 in total

1.  Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis.

Authors:  Pinelopi Arvaniti; George Giannoulis; Stella Gabeta; Kalliopi Zachou; George K Koukoulis; George N Dalekos
Journal:  JHEP Rep       Date:  2020-05-29

2.  Patient Priorities in Autoimmune Hepatitis: The Need for Better Treatments, More Education and Challenging Stigma.

Authors:  Charlotte Lloyd; Jessica Leighton; Lin Lee Wong; Anna Goulding; Ann Brownlee; Penney Gray; Emma Culver; Neil Halliday; Doug Thorburn; Michael A Heneghan; David E J Jones; Catherine Exley; Jessica K Dyson
Journal:  Dig Dis Sci       Date:  2022-05-17       Impact factor: 3.487

3.  The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis.

Authors:  Guiqiang Wang; Atsushi Tanaka; Hong Zhao; Jidong Jia; Xiong Ma; Kenichi Harada; Fu-Sheng Wang; Lai Wei; Qixia Wang; Ying Sun; Yuan Hong; Huiying Rao; Cumali Efe; George Lau; Diana Payawal; Rino Gani; Keith Lindor; Wasim Jafri; Masao Omata; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2021-05-04       Impact factor: 6.047

4.  Adverse events related to low dose corticosteroids in autoimmune hepatitis.

Authors:  Floris F van den Brand; Koen S van der Veen; Birgit I Lissenberg-Witte; Ynto S de Boer; Bart van Hoek; Joost P H Drenth; Robert C Verdonk; Jan M Vrolijk; Carin M J van Nieuwkerk; Gerd Bouma
Journal:  Aliment Pharmacol Ther       Date:  2019-10-15       Impact factor: 8.171

Review 5.  Health-related quality of life in autoimmune hepatitis.

Authors:  Romée Jalm Snijders; Piotr Milkiewicz; Christoph Schramm; Tom Jg Gevers
Journal:  World J Hepatol       Date:  2021-11-27

6.  Serum zinc concentration and quality of life in chronic liver diseases.

Authors:  Hiroki Nishikawa; Hirayuki Enomoto; Kazunori Yoh; Yoshinori Iwata; Yoshiyuki Sakai; Kyohei Kishino; Naoto Ikeda; Tomoyuki Takashima; Nobuhiro Aizawa; Ryo Takata; Kunihiro Hasegawa; Noriko Ishii; Yukihisa Yuri; Takashi Nishimura; Hiroko Iijima; Shuhei Nishiguchi
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

7.  Ubiquitously specific protease 4 inhibitor-Vialinin A attenuates inflammation and fibrosis in S100-induced hepatitis mice through Rheb/mTOR signalling.

Authors:  Jie Xu; Dazhi Chen; Lanling Jin; Zhengkang Chen; Yulu Tu; Xiaozhe Huang; Feiben Xue; Jialu Xu; Mingzhuan Chen; Xiaodong Wang; Yongping Chen
Journal:  J Cell Mol Med       Date:  2020-12-09       Impact factor: 5.295

8.  APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis.

Authors:  Hong You; Xiong Ma; Cumali Efe; Guiqiang Wang; Sook-Hyang Jeong; Kazumichi Abe; Weijia Duan; Sha Chen; Yuanyuan Kong; Dong Zhang; Lai Wei; Fu-Sheng Wang; Han-Chieh Lin; Jin Mo Yang; Tawesak Tanwandee; Rino A Gani; Diana A Payawal; Barjesh C Sharma; Jinlin Hou; Osamu Yokosuka; A Kadir Dokmeci; Darrell Crawford; Jia-Horng Kao; Teerha Piratvisuth; Dong Jin Suh; Laurentius A Lesmana; Jose Sollano; George Lau; Shiv K Sarin; Masao Omata; Atsushi Tanaka; Jidong Jia
Journal:  Hepatol Int       Date:  2022-02-04       Impact factor: 6.047

9.  Health-related quality of life in patients with autoimmune hepatitis.

Authors:  Maurice Michel; Francesca Spinelli; Annette Grambihler; Christian Labenz; Michael Nagel; Leonard Kaps; Yvonne Huber; Peter R Galle; Marcus-Alexander Wörns; Jörn M Schattenberg
Journal:  Qual Life Res       Date:  2021-05-12       Impact factor: 4.147

10.  Hepatic steatosis is highly prevalent but is not correlated with stiffness in autoimmune hepatitis.

Authors:  Sai Chalasani; Karan Mathur; Nicole Shammas; Eric Orman; Raj Vuppalanchi; Craig Lammert
Journal:  Medicine (Baltimore)       Date:  2020-10-16       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.